The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
947
Death, myocardial infarction, and urgent and non-urgent target vessel revascularization
Bleeding events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Los Angeles Cardiology Associates
Los Angeles, California, United States
Anil V. Shah, MD
Santa Ana, California, United States
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, United States
Florida Cardiovascular Research
Atlantis, Florida, United States
Ocala Research Institute, Inc
Ocala, Florida, United States
Central Florida Cardiology Group, PA
Orlando, Florida, United States
Cardiology Associates, PA
Panama City, Florida, United States
Heart Specialists of Sarasota
Sarasota, Florida, United States
Cardiac Disease Specialists
Atlanta, Georgia, United States
Emory University Hospital
Atlanta, Georgia, United States
...and 79 more locations